Carbohydrate antigen 125: a useful marker of congestion, fibrosis, and prognosis in heart failure with preserved ejection fraction

  • Published on 12/02/2024
  •  Reading time: 6 min.

Nassiba Menghoum1,2, Maria Chiara Badii1,2, Matthieu Deltombe3, Sibille Lejeune1,2, Clotilde Roy1, David Vancraeynest1,2, Agnes Pasquet1,2, Bernhard L. Gerber1,2, Sandrine Horman2, Damien Gruson3, Christophe Beauloye1,2, Anne‐Catherine Pouleur 1,2

1 Cardiovascular Department Cliniques universitaires Saint‐Luc Brussels Belgium
2 Pôle de Recherche Cardiovasculaire (CARD), Institut de Recherche Expérimentale et Clinique (IREC) Université Catholique de Louvain (UCLouvain) Brussels Belgium
3 Department of Laboratory Medicine Cliniques universitaires Saint‐Luc Brussels Belgium

Abstract

Aims Heart failure (HF) with preserved ejection fraction (HFpEF) is a disease associated with high morbidity and mortality, for which it is difficult to identify patients with the poorest prognosis in routine clinical practice. Carbohydrate antigen 125 (CA 125) has been shown to be a potential marker of congestion and prognosis in HF. We sought to better characterize HFpEF patients with high CA 125 levels by using a multimodal approach.
Methods and results...

ContentGeneMD

To continue reading this article in Full-Text...

* Access is totally free, without commitment or condition. Service exclusively reserved for healthcare professionals.

Peer-Reviewed Journals A-Z

Search | Advanced search

Get the latest news in Cardiology

Receive our newsletter to stay up to date with the latest news in Cardiology